← Back to list
Point32Health medical drug program updates
Effective date
Aug 1, 2026
Identified
Aug 4, 2026
Summary
Point32Health updated prior authorization requirements and coverage criteria for 7 medical benefit drugs across multiple plans, effective August 1 and October 1, 2026. Key changes include: Vyjuvek now covers all ages (not age-restricted), Zolgensma requires documentation of no prior gene therapy, Epioxa no longer requires prior auth for keratoconus, Imaavy has updated PA criteria, Vykoura added to step therapy, Starjemza becomes preferred ustekinumab product, and Adstiladrin PA management moved to OncoHealth.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
Get Harvard Pilgrim Health Care alertsPolicy Monitoring is free. No card required.
What to do
Action · 20 steps
01REQUIREMENTS:
By July 15, 2026 (before 8/1/2026 effective date):
- Billing team: Update billing system to remove age restrictions from Vyjuvek (J3401) coverage rules.
02System should now accept pediatric and adult claims of all ages when dystrophic epidermolysis bullosa diagnosis is present.
03- Billing team: Update Zolgensma (J3399) prior authorization templates to require provider documentation confirming member has NOT received prior gene therapy for spinal muscular atrophy (including Zolgensma or Itvisma).
04Flag claims without this documentation for denial.
05- Update encounter forms and clinical checklist in EMR to prompt providers for gene therapy history before Zolgensma ordering.
06By September 15, 2026 (before 10/1/2026 effective date):
- Billing team: Remove prior authorization requirement from Epioxa (J2789) billing rules.
07System should auto-approve claims when keratoconus diagnosis code is present; no manual PA review needed.
08- Billing team: Update Imaavy prior authorization criteria in system to require documentation of: MGFA Clinical Classification Class II-IV generalized myasthenia gravis, MG-ADL score ≥6, and refractory disease status.
09Request updated Medical Necessity Guidelines from Point32Health for specific refractory disease criteria.
10- Billing team: Add Vykoura to Medical Benefit Step Therapy logic.
11Configure system to require step therapy documentation per updated MNG.
12- Billing team: Update Targeted Immunomodulators coverage rules: Set Starjemza (ustekinumab-hmny) as preferred ustekinumab product.
13Configure system to require prior authorization denials for Yesintek unless documentation shows trial-and-failure of Starjemza or clinical rationale for continuation.
14- Billing team: Configure system to route all Adstiladrin (J9029) prior authorizations for Harvard Pilgrim Commercial and Tufts Medicare Preferred through OncoHealth vendor portal; discontinue internal PA review.
15Document OncoHealth contact information in billing team procedures.
16Consequences of inaction: Claims for Vyjuvek and Zolgensma without proper documentation will be denied.
17Epioxa claims will be improperly held for PA review.
18Imaavy authorizations may be denied for insufficient documentation.
19Yesintek claims may be approved inappropriately.
20Adstiladrin authorizations routed internally instead of OncoHealth will be delayed or denied.
Codes mentioned
J3401J3399J2789J9029
Original notice
Point32Health medical drug program updates
point32health.org · Always check the source before changing claims.
Related changes
See all Harvard Pilgrim Health Care changes →Point32Health medical drug program updatesHighEffective Oct 1, 2026 · Prior AuthorizationPoint32Health medical drug program updatesMediumEffective Nov 1, 2026 · Prior AuthorizationPoint32Health medical drug program updatesHighEffective Jul 1, 2026 · Prior AuthorizationPoint32Health medical drug program updatesHighEffective Aug 1, 2025 · Provider NewsletterBrowse every Harvard Pilgrim Health Care change in the policy list